Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors. The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline to achieve multiple clinical value catalysts.
The Series C round was co-led by Andera Partners, Bpifrance (through its InnoBio 2 fund) and M Ventures, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, XGen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
Walder Wyss advised the investors in the transaction. The team was led by partner Alexander Gutmans (pictured left) and senior associate Karina Tschon (both corporate/M&A and venture capital, pictured right), and further included Benjamin Suter (counsel, commercial contracts), Michelle Bruni (managing associate, tax), associates Lucas Maurer, Simon Olstein and Christoph Burckhardt (all corporate/M&A and venture capital) and Dario Glauser (associate, employment).